Clonal hematopoiesis

Tempus Announces 18 Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
Research, Managed Care, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, Mutation, Survival, ESR1, Intelligence, Progression-free survival, Patient, NGS, DNA, MD, Medicine, Abstract, AACR, TRM, Clonal hematopoiesis, AIS, Liquid biopsy, Enzyme inhibitor, Annual general meeting, Medical imaging

Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.
  • Tempus researchers will demonstrate how the company’s AI-enabled precision medicine platform collects and analyzes high-quality, multimodal datasets to advance cancer research.
  • “We look forward to presenting 18 abstracts at AACR this year, demonstrating the breadth and depth of our research both at Tempus and with our biopharma collaborators,” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus.
  • These preliminary findings suggest that xM used for TRM can identify patients with ESR1m and poor response on AI who may benefit from switching therapy.

Foundation Medicine Announces Details of Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Technology, FDA, Health, Pharmaceutical, Oncology, Other Science, Research, Artificial Intelligence, Science, Clinical Trials, NSCLC, Cancer, Clonal hematopoiesis, Doctor of Philosophy, Artificial intelligence, Immunotherapy, Neoplasm, Pathology, TME, PCG, Effectiveness, AACR, Interface, Data, HER2, Lung cancer, Genentech, Flatiron, Roche, Biomarker, Tumor microenvironment, Abstract, Patient, Survival, Foundation Medicine, Plasma, DNA, Medical imaging

Foundation Medicine, Inc ., a genomics company dedicated to transforming cancer care, today announced that research from its robust oncology diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California April 5-10, 2024.

Key Points: 
  • Foundation Medicine, Inc ., a genomics company dedicated to transforming cancer care, today announced that research from its robust oncology diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California April 5-10, 2024.
  • ​Results suggest ​serial early ctDNA monitoring ​is a valuable complementary tool for real-time treatment response monitoring to targeted therapy.
  • These findings may enable personalized therapy approaches tailored to a patient’s risk of progression and downstream cancer treatment planning.
  • Follow Foundation Medicine on LinkedIn and X for more updates from #AACR24 and visit us in person at booth #3117.

DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay

Retrieved on: 
Thursday, February 1, 2024
Liquid biopsy, MAF, Immunocore, Research, Clonal hematopoiesis, PALO, Patient, DELFI, TCR, ImmTAC, RUO, Neoplasm, Cancer, Plasma, Nucleic acid thermodynamics

PALO ALTO, Calif. and BALTIMORE, Feb. 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced availability of the company's fragmentome-based research use only (RUO) cancer monitoring assay. The DELFI-Tumor Fraction (DELFI-TF) assay is a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer.

Key Points: 
  • PALO ALTO, Calif. and BALTIMORE, Feb. 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced availability of the company's fragmentome-based research use only (RUO) cancer monitoring assay.
  • The DELFI-Tumor Fraction (DELFI-TF) assay is a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer.
  • Additionally, DELFI announced a new research collaboration with Immunocore Holdings plc (Nasdaq: IMCR) – a commercial-stage biotechnology company pioneering the development of a novel class of bispecific T cell receptor (TCR) immunotherapies against cancer (ImmTAC molecules) – focused on exploring the use of the DELFI-TF cancer monitoring assay as an early predictor of benefit from treatment with ImmTAC-based therapies.
  • "We are excited that Immunocore will be further exploring the clinical and research potential of the DELFI liquid biopsy platform as a new approach to monitoring treatment response."

Tempus Introduces xM to Assess Minimal Residual Disease (MRD) in Patients with Colorectal Cancer (CRC) for Research Use Only

Retrieved on: 
Thursday, January 18, 2024
Technology, Research, Surgery, Medical Devices, Health Technology, Health, Science, Artificial Intelligence, Oncology, Clonal hematopoiesis, Patient, MRD, Neoplasm, DNA, CHIP, Liquid biopsy, DX, Intelligence, Chief Justice of Hungary, Algorithm, Lung cancer, Risk, Methylation, Recurrence, Plasma, NeXT, LDT, Doctor of Philosophy, Artifact, CRC, Medicine, Blood, Medical imaging

Tempus, a leader in artificial intelligence and precision medicine, today announced the addition of a novel MRD assay, xM, to its comprehensive testing solutions.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced the addition of a novel MRD assay, xM, to its comprehensive testing solutions.
  • The tumor-naïve plasma based test is available for research use only to detect circulating tumor DNA (ctDNA) in the blood of patients with early stage CRC after surgery.
  • xM is a liquid biopsy approach to MRD assessment, where no baseline tumor tissue is required.
  • “Colorectal cancer is the second leading cause of cancer-related deaths worldwide,1 and surgical intervention alone may not be curative for all patients.

Mission Bio Announces Over 20 Presentations Demonstrating the Utility of Tapestri Across AML, Multiple Myeloma, and Lymphoma at the 2023 ASH Annual Meeting

Retrieved on: 
Thursday, December 7, 2023
Science, Other Science, Research, Oncology, General Health, Health, Genetics, Clinical Trials, Harvard University, Multiple myeloma, Bone marrow, Identification, Landscape, DNA, MIT, ASH, Clonal hematopoiesis, University of Navarra, MFC, Patient, PCR, Mission, Cell, Medicine, Differentiation, MD Anderson Cancer Center, B cell, MRD, Merck, Blood, CNV, Flow cytometry, Exposition, MD, Survival, AML, Doctor of Philosophy, Society, Translational medicine, Genetic heterogeneity, Hospital, Genentech, Pharmaceutical industry, Vaccine, Hematology, Franses Tapestry Archive

The widespread adoption of Tapestri for hematological research and therapeutic development signifies the importance of single-cell multi-omic data and indicates a potential new gold standard in precision medicine.

Key Points: 
  • The widespread adoption of Tapestri for hematological research and therapeutic development signifies the importance of single-cell multi-omic data and indicates a potential new gold standard in precision medicine.
  • Detected MRD-positive patients, which were deemed negative by MFC and PCR,
    Differentiated between clonal hematopoiesis (CH) clones and leukemic clones.
  • Data from other blood cancer studies will be presented by leading researchers in over 24 presentations leveraging Mission Bio’s Tapestri Platform, showcasing its broad application in hematology.
  • For a complete list of ASH presentations using Tapestri, please visit our website .

Powered by Its Industry-Leading Comprehensive Multi-Omic Database, Caris Life Sciences to Showcase Research at the 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, December 4, 2023
PD-L1, Senior, Patient, Triple-negative breast cancer, Neoplasm, Prognosis, MBA, Cancer, Diagnosis, Doctor of Philosophy, Overalls, Clinical professor, Malignancy, NGS, Female, AI, Pregnancy, RNA, ID, BCL2, Brown University, Breast, FACP, Immunology, Breast cancer, Clonal hematopoiesis, Dana–Farber Cancer Institute, NTRK1, Disease, Phyllodes tumor, HER2, TNBC, Targeted therapy, Research, MPT, China Tribunal, NCI, Medicine, Genomics, POA, MD, Survival, Mayo Clinic, Concurrency, Biology, Dentistry, Pharmaceutical industry, Birth control, Medical imaging, Vaccine, Male, Caris

IRVING, Texas, Dec. 4, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present findings at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer. The findings demonstrate the power of Caris' comprehensive clinico-genomic database that enables novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan, and response to treatment. SABCS is being held December 5-9, 2023 (Booth #1433) in San Antonio, Texas.

Key Points: 
  • "The San Antonio Breast Cancer Symposium continues to be the premiere conference for breast cancer research," said George W. Sledge, Jr. , MD, Executive Vice President and Chief Medical Officer of Caris.
  • "As part of our continuing commitment to the breast cancer community, Caris is proud to share important clinical/translational research created with our academic partners on important breast cancer questions."
  • The results of this analysis indicate that male breast cancer has differential molecular and immune features compared to female breast cancer.
  • Caris will present additional data from studies demonstrating the critical role of precision medicine and molecular profiling in the treatment of breast cancer.

Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition

Retrieved on: 
Monday, November 6, 2023
Stem cell, Genetic distance, Haematopoiesis, Peripheral artery disease, Epidemiology, Smoking, Clonal hematopoiesis, Lung cancer, Genetics, Mortality, Bone marrow, Health, Carcinoma, UK Biobank, CH, Emphysema, Genome, Disease, Risk, HSC, AMGN, Gene, Chronic obstructive pulmonary disease, Gene expression, Mutation, Cardiovascular disease, Vaccine, Amgen, Nature Genetics

Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.

Key Points: 
  • Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.
  • The study reaffirmed that clonal hematopoiesis is very common in the elderly, approaching 50% in people over 80 years old.
  • Clonal hematopoiesis has many of the hallmarks of a premalignant expansion of cell clones with a potential to become cancerous.
  • Overall, the study has provided substantial insights into the genetics and epidemiology of clonal hematopoiesis.

Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition

Retrieved on: 
Monday, November 6, 2023
Stem cell, Genetic distance, Haematopoiesis, Peripheral artery disease, Epidemiology, Smoking, Clonal hematopoiesis, Lung cancer, Genetics, Mortality, Bone marrow, Health, Carcinoma, UK Biobank, CH, Emphysema, Genome, Disease, Risk, HSC, AMGN, Gene, Chronic obstructive pulmonary disease, Gene expression, Mutation, Cardiovascular disease, Vaccine, Amgen, Nature Genetics

Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.

Key Points: 
  • Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.
  • The study reaffirmed that clonal hematopoiesis is very common in the elderly, approaching 50% in people over 80 years old.
  • Clonal hematopoiesis has many of the hallmarks of a premalignant expansion of cell clones with a potential to become cancerous.
  • Overall, the study has provided substantial insights into the genetics and epidemiology of clonal hematopoiesis.

Florida Cancer Specialists & Research Institute Cutting-Edge Clinical Research Presented at 2023 ASCO® Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
Abstract (summary), Education, Pulmonary embolism, Head, FACP, Cancer, Uveal melanoma, Research, Publication, Lung cancer, Doctor of Philosophy, ASCO, Clonal hematopoiesis, American Society of Clinical Oncology, MD, Patient, Physician, Melanoma, Annual general meeting, Drug development, Ovarian cancer, Breast cancer, Health, Society, Conference, FCS, Nursing, Pharmaceutical industry, Dietary supplement, Birth control, Medical imaging, Glass wool

FORT MYERS, Fla., June 1, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) physicians are presenting the outcomes of 23 clinical trials, the majority being Phase 1, at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting on June 2 – 6 in Chicago, Illinois. With over 120 abstract sub-categories, attendees will learn about the most advanced treatments, research and innovations in oncology care on a global scale.

Key Points: 
  • Florida Cancer Specialists & Research Institute to present 23 abstracts/publications at 2023 ASCO Annual Conference.
  • Many of the featured studies being presented at the 2023 ASCO® Annual Meeting originated from trials conducted at the three FCS Phase 1 Drug Development Units and from late-phase studies conducted at FCS clinics located throughout Florida.
  • The American Society of Clinical Oncology (ASCO®) represents nearly 45,000 oncology professionals who care for people living with all forms of cancer.
  • Through research, education and promotion of high quality and equitable patient care, ASCO works to conquer cancer.

Genomic Testing Cooperative Presents at ASCO meeting Studies Demonstrating the Power of its Liquid Biopsy and Tissue-Based Targeted Transcriptomic Approach when Combined with Artificial Intelligence

Retrieved on: 
Wednesday, May 31, 2023
Research, Technology, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, DNA, LCA, The, Neoplasm, NGS, Liquid biopsy, Cancer, Ageing, Medicine, Biomarker, RNA, ASCO, GTC, CHIP, Clonal hematopoiesis, American Society of Clinical Oncology, Cooperative, CFRNA, Artificial intelligence, Diagnosis, AI, Society, Medical imaging

Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting three studies illustrating the power of its proprietary RNA next generation sequencing (NGS) approach in advancing liquid biopsy and tissue-based precision testing.

Key Points: 
  • Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting three studies illustrating the power of its proprietary RNA next generation sequencing (NGS) approach in advancing liquid biopsy and tissue-based precision testing.
  • In another study, GTC presents data showing that its AI selected only 20 immune biomarkers that can distinguish between immunologically active tumors and immunologically inactive tumors.
  • Similarly, GTC’s proprietary AI using targeted transcriptomic data can define specific immune microenvironment biomarkers that distinguish myelodysplastic bone marrow from acute leukemia microenvironment and from normal bone marrow.
  • “These studies form the basis for establishing new innovative approaches that can be used in the diagnosis and the treatment of cancer.